AmCad BioMed Corporation Statistics
AmCad BioMed Corporation (4188) Stock Statistics & Valuation Metrics
Total Valuation
AmCad BioMed Corporation has a market cap or net worth of TWD 867.66M. The enterprise value is TWD 650.40M.
- Market Cap
- TWD 867.66M
- Enterprise Value
- TWD 650.40M
Share Statistics
AmCad BioMed Corporation has 63,332,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 63,332,900
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
AmCad BioMed Corporation’s return on equity (ROE) is -0.11 and return on invested capital (ROIC) is -14.51%.
- Return on Equity (ROE)
- -0.11
- Return on Assets (ROA)
- -0.09
- Return on Invested Capital (ROIC)
- -14.51%
- Return on Capital Employed (ROCE)
- -0.15
- Revenue Per Employee
- 437.464
- Profits Per Employee
- -800.836
- Employee Count
- 69,576
- Asset Turnover
- 0.05
- Inventory Turnover
- 0.75
Valuation Ratios
The current PE Ratio of AmCad BioMed Corporation is -15.00. AmCad BioMed Corporation’s PEG ratio is 1.01.
- PE Ratio
- -15.00
- PS Ratio
- 31.95
- PB Ratio
- 1.59
- Price to FCF
- -17.63
- Price to Operating Cash Flow
- -17.37
- PEG Ratio
- 1.01
Income Statement
In the last 12 months, AmCad BioMed Corporation had revenue of 30.44M and earned -55.72M in profits. Earnings per share was -0.88.
- Revenue
- 30.44M
- Gross Profit
- 10.02M
- Operating Income
- -87.95M
- Pretax Income
- -71.40M
- Net Income
- -55.72M
- EBITDA
- -55.52M
- Earnings Per Share (EPS)
- -0.88
Cash Flow
In the last 12 months, operating cash flow was -47.31M and capital expenditures -120,000, giving a free cash flow of -47.43M billion.
- Operating Cash Flow
- -47.31M
- Free Cash Flow
- -47.43M
- Free Cash Flow per Share
- -0.76
Dividends & Yields
AmCad BioMed Corporation pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.57%
- Earnings Yield
- -6.63%
Stock Price Statistics
- Beta
- 0.53
- 52-Week Price Change
- -14.87%
- 50-Day Moving Average
- 14.63
- 200-Day Moving Average
- 12.49
- Relative Strength Index (RSI)
- 42.32
- Average Volume (3m)
- 340.10K
Important Dates
AmCad BioMed Corporation upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
AmCad BioMed Corporation as a current ratio of 22.62, with Debt / Equity ratio of 0.91%
- Current Ratio
- 22.62
- Quick Ratio
- 21.11
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.36
- Interest Coverage Ratio
- -999.49
Taxes
In the past 12 months, AmCad BioMed Corporation has paid -15.00K in taxes.
- Income Tax
- -15.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
AmCad BioMed Corporation EV to EBITDA ratio is -12.75, with an EV/FCF ratio of -17.90.
- EV to Sales
- 29.69
- EV to EBITDA
- -12.75
- EV to Free Cash Flow
- -17.90
- EV to Operating Cash Flow
- -17.95
Balance Sheet
AmCad BioMed Corporation has TWD 341.88M in cash and marketable securities with TWD 13.35M in debt, giving a net cash position of TWD 328.54M billion.
- Cash & Marketable Securities
- TWD 341.88M
- Total Debt
- TWD 13.35M
- Net Cash
- TWD 328.54M
- Net Cash Per Share
- TWD 5.19
- Tangible Book Value Per Share
- TWD 8.31
Margins
Gross margin is 22.42%, with operating margin of -346.18%, and net profit margin of -248.85%.
- Gross Margin
- 22.42%
- Operating Margin
- -346.18%
- Pretax Margin
- -275.18%
- Net Profit Margin
- -248.85%
- EBITDA Margin
- -307.67%
- EBIT Margin
- -338.29%
Analyst Forecast
The average price target for AmCad BioMed Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -39.87%
- EPS Growth Forecast
- -14.87%
